1Settimana·

New 100% er?

After things have been going very well with equity investments recently, I added 2 new opportunities to my portfolio yesterday, with a target of at least 100%.

The first would be $GPCR . A biotech company. Developed in the slimming market. According to initial studies, the preparation is said to have improved the effectiveness of $NOVO B (-2,31%) and $LLY (-2,68%) in some areas.

In addition to the chance of positive market launches, I also see good opportunities for takeovers by pharmaceutical giants who also want a foothold in the market.

27.08
GPC
Acquistato a 18,39 USD
20
46 Commenti

immagine del profilo
1Settimana
I like your ideas! Always original and well-founded.
Neither dull mainstream nor clumsy momentum chasing.
If it works from time to time, it's worth your while! 💪
13
immagine del profilo
@Epi That's how I see it too
1
1Settimana
How on earth do you always come up with something like that?
Such sensible explanations always tempt you to join in :-)
2
immagine del profilo
1Settimana
@Migu11 Who do you mean?
1Settimana
The @Multibagger grad with its companies.... with you anyway, I only say the 3x Coffee ^^
1
immagine del profilo
1Settimana
@Migu11 Yes, the $3CFL! +100% in 4 weeks. Unfortunately I wasn't there this time. 🤷
immagine del profilo
@Migu11 I'm glad you think so. Just as I have already benefited from some of the ideas here, I always try to provide added value.
1
immagine del profilo
1Settimana
Hey Chris, interesting thing you've dug up there. I'll throw one out there too - also for my homie @Tenbagger2024 😎 But, please remember, it's another small cap and just an idea for now, with mmn very good growth potential $PNG otherwise $SPAI is also accelerating (after $ONDS took a private placement), but I'm not running after it now, but waiting until it comes down a bit (and enjoying the chart of $ONDS 😎)
2
immagine del profilo
@toscho Good morning. $PNG has been on my watchlist for some time. But I haven't bought it yet, which doesn't speak against the company, but because I have always found other investment cases that I thought would perform better in a shorter period of time. And unfortunately I can't buy all the interesting stocks with the current size of my portfolio.
immagine del profilo
1Settimana
@Multibagger oh, tell me about it... BUT the small caps are additions, my core of quality stocks is the real focus. I always have to discipline myself not to forget that. All the best for the future and never FOMO 😉
1
immagine del profilo
1Settimana
Brave to get in there
1
immagine del profilo
@Sebi97 If you want 100% or more, you just have to take a little more risk. I'm aware of that and I'm fine with it
immagine del profilo
Good luck my best. I am still looking for commodity stocks to improve my tech exposure
1
immagine del profilo
@Wiktor_06 Did you not like my suggestions? 😉 Or did they go too well for you?
immagine del profilo
@Multibagger have gone too well 😂, unfortunately
1
immagine del profilo
@Wiktor_06 you should have asked me 3 months ago!😂 I already had almost all of them then too.😎
immagine del profilo
@Multibagger now I'm looking for new ones ...: to get rid of this dirty techiness
1
immagine del profilo
@Wiktor_06 let me know when you've found some. Have a look at my 2 secret favorites. Maybe they are something for you.
$MEI and not quite so secret anymore $MTM.
immagine del profilo
@Multibagger everything that has already made 400%😂 and the other thing is to find them on Trade Republic 😂
1
immagine del profilo
@Multibagger I've just been reading up on $IPX on the train. But everyone already has this realy, and buying in all time high is ass
1
immagine del profilo
@Wiktor_06 well, if a share rises from 2 ct to 9ct, that's 400%, but it can still easily rise to 10$. $MTM is available on TR.
Good shares are never cheap once they have been discovered. $IPX has what it takes to become a 100 bagger. My first target price is €7. Then it goes on. I see at least €25 by 2030.
immagine del profilo
@Wiktor_06 There are also trends that I missed. $PLTR or $NVDA. I made very good money with the latter several times with short-term derivative trades, but I missed the share rally.
immagine del profilo
@Wiktor_06 and if you look around in other sectors apart from raw materials to reduce the technology gap? I still find biotechnology exciting. I don't think you count it as tech.
Visualizza tutti 8 ulteriori risposte
immagine del profilo
May I ask what sums you invest in such trades?
1
immagine del profilo
@TomTurboInvest normally 1.5%-2% of my portfolio volume in the first tranche, which as you know is still small.
1
immagine del profilo
How high is your custody account volume, I'm sure most people are now asking themselves😆
immagine del profilo
@Julius_Gru ca. 15TE
immagine del profilo
Chat Gpt says: The weighted expected price across all scenarios (incl. M&A opportunity) is USD 45.35. I remain curious, and perhaps I will also take a small tranche 😉
1
immagine del profilo
@Steppenwolf66 I'll take those😉
1
immagine del profilo
Hmmm... Neither tradable via SC, TR or Zero. What kind of witchcraft is that? 😂
1
immagine del profilo
@TradingHase it is actually only directly tradable in the USA so far. As I only trade US stocks there anyway, I hadn't noticed this before.
1
immagine del profilo
@Multibagger That's an explanation 😉
immagine del profilo
1Settimana
Wouldn't $VKTX be the better choice? Syringe had very good data from phase 2
immagine del profilo
@chrxschaaan but the drop-out rates in the first treatment cycle due to side effects are catastrophically high.
immagine del profilo
1Settimana
@chrxschaaan Yes, they were extreme with the tablet but with the injection 15% weight loss in 13 weeks, 10% dropout rate.
You can't know what will come out of phase 3 but I think the chance is pretty attractive, could be the strongest 💉 well, or nothing at all 😁😁
1
immagine del profilo
@chrxschaaan Biotech is always a bet on study results.
2
immagine del profilo
@Multibagger And who pays for the study...
immagine del profilo
I like the community and the ideas here. I feel more comfortable here than with the turquoise-blue competitor.
Partecipa alla conversazione